Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
Date
2024-03-01ICR Author
Author
de Jager, VD
Timens, W
Bayle, A
Botling, J
Brcic, L
Büttner, R
Fernandes, MGO
Havel, L
Hochmair, M
Hofman, P
Janssens, A
van Kempen, L
Kern, I
Machado, JC
Mohorčič, K
Popat, S
Ryška, A
Wolf, J
Schuuring, E
van der Wekken, AJ
Type
Journal Article
Metadata
Show full item recordAbstract
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.
Collections
Subject
Next-generation sequencing
Non-small cell lung cancer
Predictive biomarker testing
Language
eng
Date accepted
2024-01-08
License start date
2024-03-01
Citation
The Lancet Regional Health - Europe, 2024, 38 pp. 100839 -
Publisher
Elsevier BV